Alvotech (ALVO) Operating Expenses (2021 - 2026)
Alvotech's (ALVO) quarterly Operating Expenses came in at -$65.4 million in Q2 2026, up 19.7% on a YoY basis from -$54.6 million in Q2 2025, and down 30.35% quarter-over-quarter from -$50.2 million in Q1 2026.
Analysis
Alvotech (ALVO) Operating Expenses (2021 - 2026) Analysis & Trends
Alvotech (ALVO) has reported Operating Expenses for 6 consecutive years, with -$65.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Operating Expenses rose 19.7% year-over-year to -$65.4 million; the trailing twelve-month figure through Jun 2026 stood at -$331.4 million (up 22.16% YoY), and the FY2025 full-year result was -$275.1 million, down 16.08% from the prior year.
- Operating Expenses declined to -$65.4 million in Q2 2026 per ALVO's latest filing, from -$50.2 million in the prior quarter.
- Across five years, Operating Expenses topped out at $593.4 million in Q2 2022 and bottomed at -$367.4 million in Q1 2022.
- Historically, Operating Expenses has averaged -$113.1 million across 5 years, with a median of -$79.5 million in 2025.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses plunged 111.53% in 2023, then soared 77.26% in 2024.
- Over 5 years, Operating Expenses stood at -$367.4 million in 2022, then advanced by 21.77% to -$287.4 million in 2023, then rose by 17.52% to -$237.0 million in 2024, then soared by 41.68% to -$138.2 million in 2025, then soared by 52.68% to -$65.4 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered -$65.4 million, -$50.2 million, and -$138.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.74 Bn | 39.09 Bn | 2.15 Bn | 1.29 Bn |
| 2 | Viatris | 19.12 Bn | 18.23 Bn | 1.46 Bn | 1.45 Bn |
| 3 | Dr Reddys Laboratories | 9.85 Bn | 9.68 Bn | 396.53 Mn | 356.56 Mn |
| 4 | Amneal Pharmaceuticals | 5.47 Bn | 5.35 Bn | 334.51 Mn | 195.34 Mn |
| 5 | Bausch Health Companies | 2.37 Bn | 530.13 Mn | 2.10 Bn | 2.11 Bn |
| 6 | Alvotech | 1.51 Bn | 1.36 Bn | 2.56 Mn | -65.41 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 225.58 Mn |
| 8 | Amphastar Pharmaceuticals | 991.81 Mn | 701.69 Mn | 93.47 Mn | 53.74 Mn |
| 9 | Fennec Pharmaceuticals | 412.12 Mn | 370.87 Mn | 17.15 Mn | 16.14 Mn |
| 10 | RedHill Biopharma | 182.76 Mn | 182.76 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -65.41 Mn |
| Mar 31, 2026 | -50.18 Mn |
| Dec 31, 2025 | -138.24 Mn |
| Sep 30, 2025 | -77.54 Mn |
| Jun 30, 2025 | -81.46 Mn |
| Mar 31, 2025 | -56.78 Mn |
| Dec 31, 2024 | -237.03 Mn |
| Sep 30, 2024 | -50.45 Mn |
| Jun 30, 2024 | -61.68 Mn |
| Mar 31, 2024 | -65.36 Mn |
| Dec 31, 2023 | -287.39 Mn |
| Aug 31, 2023 | -141.49 Mn |
| Jun 30, 2023 | -68.43 Mn |
| Mar 20, 2023 | -287.39 Mn |
| Dec 31, 2022 | -367.36 Mn |
| Aug 31, 2022 | -226.03 Mn |
| Jun 30, 2022 | 593.40 Mn |
| Mar 20, 2022 | -367.36 Mn |
| Dec 31, 2021 | -275.14 Mn |
| Sep 30, 2021 | -76.15 Mn |